Emmanuel Lacroix
Partner @ UCB Ventures
Brussels, Belgium
Emmanuel Lacroix is a seed investor at UCB Ventures in Brussels focused on Biotechnology. Emmanuel Lacroix joined UCB Ventures in March 2017, as Senior Director, Venture Investments. He is currently a member of the Board of Syndesi Therapeutics, a UCB spinout company that he helped to launch in early 2018. Syndesi Therapeutics develops novel therapeutics addressing cognitive deficits in, for example, people with Alzheimer'sDisease. Emmanuel also holds a Board observer position with Lumos Pharma, a company developing therapeutics for rare and neglected diseases, with focus on neurodevelopment disorders.Emmanuel served as UCB's Head of Business Development Neurology where he was instrumental to the execution of multiple partnership and license agreements, product acquisitions, and other investments, including the discovery collaboration with Q-State Bioscience in Epilepsy; the R&D partnership with Neuropore Therapies in Parkinson's Disease; and the Series A and B investments in Lumos Pharma. In an earlier Sales and Global Marketing position, Emmanuel contributed to the coordination of global pre-launch activities for Vimpat® and the business planning for UCB's other CNS products.Before joining UCB, Emmanuel led multidisciplinary teams at Cellectis SA, a biotechnology start-up. He received an MBA from IMD (Switzerland), a PhD in Molecular Biology from ULB (Belgium) based on protein engineering research conducted at the European Molecular Biology Laboratory (Germany), and a MSc in Biochemistry from the ULG (Belgium).
- Total investments:
- 1
- Last investment:
- Lead investor:
- 100%
Last updated:
For AI agents: llms.txt
Industries Emmanuel Lacroix invests in
Stages Emmanuel Lacroix invests in
Countries Emmanuel Lacroix invests in
Investments
| Company | Description | Round | Links |
|---|---|---|---|
EsoBiotec
|
EsoBiotec is a Belgian biotechnology business focused on the discovery of novel cancer therapies.EsoBiotec's objective is to enable the human body to fight cancer by delivering 'in vivo' cell engineering to patients. | $3.5M / Seed / Sep 30, 2021 |
Co-Investors
About UCB Ventures
UCB Ventures is a €150 million strategic corporate venture fund
UCB Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Alicia Iruzun Lafitte
Partner
|
|||
|
Emmanuel Lacroix
Partner
|
|||
Delphine Hajaji
Partner
|
|||
Erica Whittaker
Head of UCB Ventures
|
|||
Joshua Sands
Principal
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Emmanuel Lacroix invest in?
Emmanuel Lacroix invests primarily in Biotechnology startups, most often at Seed stage. Most of the 1 investments tracked by Shizune back companies in Belgium. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Emmanuel Lacroix last invest?
The most recent investment recorded for Emmanuel Lacroix closed in Sep 2021. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
